miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis

Zhang,Ke‑Jing; Hu,Yu; Luo,Na; Li,Xin; Chen,Fei‑Yu; Yuan,Jia‑Qi; Guo,Lei

doi:10.3892/ijo.2020.4995

miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis

Authors:
- Ke‑Jing Zhang
- Yu Hu
- Na Luo
- Xin Li
- Fei‑Yu Chen
- Jia‑Qi Yuan
- Lei Guo
View Affiliations

Affiliations: Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 20, 2020 https://doi.org/10.3892/ijo.2020.4995
Pages: 1240-1251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is a subtype of breast cancer with a high degree of malignancy. TNBC is prone to distant metastasis and has a poor prognosis. A number of TNBC‑related microRNAs (miRNAs) have been studied and identified. However, the detailed roles of miR‑574‑5p in TNBC remain poorly understood. miR‑574‑5p, SRY (sex determining region Y)‑box 2 (SOX2), B‑cell lymphoma/leukaemia 11A (BCL11A), SKI like proto‑oncogene (SKIL) and epithelial‑mesenchymal transition (EMT)‑related miRNAs and proteins were measured by reverse transcription‑quantitative PCR and western blotting analysis, respectively. A luciferase reporter assay was employed to validate the direct targeting of SOX2 and BCL11A by miR‑574‑5p. MTT, colony formation and Transwell assays were performed to analyse the biological functions of miR‑574‑5p in TNBC cells. A nude mouse xenograft model was used to verify the effects of miR‑574‑5p on the tumorigenesis of TNBC in vivo. The results demonstrated that miR‑574‑5p levels were decreased in breast cancer tissues and cells. miR‑574‑5p repressed proliferation, migration and EMT in TNBC cells. Further experiments confirmed that miR‑574‑5p reduced tumour size and metastasis in vivo. miR‑574‑5p targeted BCL11A and SOX2 to inhibit the SKIL/transcriptional co‑activator with PDZ‑binding motif/connective tissue growth factor axis, and the inhibitory effect of miR‑574‑5p in TNBC cells was at least partly dependent on SOX2 and BCL11A. In addition, the regulation of downstream oncogenes by SOX2 was dependent on BCL11A. To the best of our knowledge, this is the first study to report the association between the miR‑574‑5p/BCL11A/SOX2 axis and the tumorigenesis of TNBC, which provides a new mechanism for understanding the progression of TNBC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, et al: Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis. Cancer Res. 78:671–684. 2018. View Article : Google Scholar
3	Kumar P and Aggarwal R: An overview of triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269. 2016. View Article : Google Scholar
4	Liu F, Zhuang L, Wu R and Li D: miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10. J BUON. 24:1905–1912. 2019.PubMed/NCBI
5	Denkert C, Liedtke C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 389:2430–2442. 2017. View Article : Google Scholar
6	Yu Y, Wang J, Khaled W, Burke S, Li P, Chen X, Yang W, Jenkins NA, Copeland NG, Zhang S and Liu P: Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med. 209:2467–2483. 2012. View Article : Google Scholar : PubMed/NCBI
7	Nakamura T, Yamazaki Y, Saiki Y, Moriyama M, Largaespada DA, Jenkins NA and Copeland NG: Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product. Mol Cell Biol. 20:3178–3186. 2000. View Article : Google Scholar : PubMed/NCBI
8	Chen F, Luo N, Hu Y, Li X and Zhang K: MiR-137 suppresses triple-negative breast cancer stemness and tumorigenesis by perturbing BCL11A-DNMT1 interaction. Cell Physiol Biochem. 47:2147–2158. 2018. View Article : Google Scholar : PubMed/NCBI
9	Lazarus KA, Hadi F, Zambon E, Bach K, Santolla MF, Watson JK, Correia LL, Das M, Ugur R, Pensa S, et al: BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nat Commun. 9:33272018. View Article : Google Scholar : PubMed/NCBI
10	Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, et al: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 511:246–250. 2014. View Article : Google Scholar : PubMed/NCBI
11	Mamun MA, Mannoor K, Cao J, Qadri F and Song X: SOX2 in cancer stemness: Tumor malignancy and therapeutic potentials. J Mol Cell Biol. Dec 5–2018.Epub ahead of print. PubMed/NCBI
12	Tong B, Zeng J, Wu Y and Xiong W: Enhanced SOX2 expression in retinoblastoma tissues and peripheral blood is associated with the clinicopathological characteristics of the disease. Oncol Lett. 9:1244–1248. 2015. View Article : Google Scholar : PubMed/NCBI
13	Nomura N, Sasamoto S, Ishii S, Date T, Matsui M and Ishizaki R: Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 17:5489–5500. 1989. View Article : Google Scholar : PubMed/NCBI
14	Jahchan NS and Luo K: SnoN in mammalian development, function and diseases. Curr Opin Pharmacol. 10:670–675. 2010. View Article : Google Scholar : PubMed/NCBI
15	Shinozuka E, Miyashita M, Mizuguchi Y, Akagi I, Kikuchi K, Makino H, Matsutani T, Hagiwara N, Nomura T, Uchida E and Takizawa T: SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells. Biochem Biophys Res Commun. 430:101–106. 2013. View Article : Google Scholar
16	Kodigepalli KM, Anur P, Spellman P, Sims PJ and Nanjundan M: Phospholipid Scramblase 1, an interferon-regulated gene located at 3q23, is regulated by SnoN/SkiL in ovarian cancer cells. Mol Cancer. 12:322013. View Article : Google Scholar : PubMed/NCBI
17	Javelaud D, van Kempen L, Alexaki VI, Le Scolan E, Luo K and Mauviel A: Efficient TGF‑β/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression. Mol Cancer. 10:22011. View Article : Google Scholar
18	Makino Y, Yoon JH, Bae E, Kato M, Miyazawa K, Ohira T, Ikeda N, Kuroda M and Mamura M: Repression of Smad3 by Stat3 and c‑Ski/SnoN induces gefitinib resistance in lung adeno-carcinoma. Biochem Biophys Res Commun. 484:269–277. 2017. View Article : Google Scholar : PubMed/NCBI
19	Sengupta S, Jana S, Biswas S, Mandal PK and Bhattacharyya A: Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells. Clin Exp Metastasis. 30:1019–1031. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, Martin GS, Sun L and Luo K: Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol. 27:324–339. 2007. View Article : Google Scholar :
21	Band AM and Laiho M: SnoN oncoprotein enhances estrogen receptor-α transcriptional activity. Cell Signal. 24:922–930. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhu Q, Le Scolan E, Jahchan N, Ji X, Xu A and Luo K: SnoN antagonizes the hippo kinase complex to promote TAZ signaling during breast carcinogenesis. Dev Cell. 37:399–412. 2016. View Article : Google Scholar : PubMed/NCBI
23	Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ and Yang X: The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. 78:1457–1470. 2018. View Article : Google Scholar : PubMed/NCBI
24	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
25	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tian Y, Fu X, Li Q, Wang Y, Fan D, Zhou Q, Kuang W and Shen L: MicroRNA181 serves an oncogenic role in breast cancer via the inhibition of SPRY4. Mol Med Rep. 18:5603–5613. 2018.PubMed/NCBI
27	Krutzfeldt J: Strategies to use microRNAs as therapeutic targets. Best Pract Res Clin Endocrinol Metab. 30:551–561. 2016. View Article : Google Scholar : PubMed/NCBI
28	Peng G, Liao Y and Shen C: miRNA-429 inhibits astrocytoma proliferation and invasion by targeting BMI1. Pathol Oncol Res. 23:369–376. 2017. View Article : Google Scholar
29	Deng Z, Wang Y, Fang X, Yan F, Pan H, Gu L, Xie C, Li Y, Hu Y, Cao Y and Tang Z: Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. Cancer Gene Ther. 24:282–288. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, Chuang YC, Yang CN, Ger LP, Chen YC, et al: A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene. 37:4662–4678. 2018. View Article : Google Scholar : PubMed/NCBI
31	Huang X and Yin YM: Updates of chinese society of clinical oncology (CSCO) guideline for breast cancer in 2018. Zhonghua Yi Xue Za Zhi. 98:1213–1217. 2018.In Chinese. PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
33	Shah MY and Calin GA: MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA. 5:537–548. 2014. View Article : Google Scholar : PubMed/NCBI
34	D'Ippolito E and Iorio MV: MicroRNAs and triple negative breast cancer. Int J Mol Sci. 14:22202–22220. 2013. View Article : Google Scholar : PubMed/NCBI
35	Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, Lin WC, Shen CY, Huang CS, Hsieh FJ, et al: Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer. 14:362015. View Article : Google Scholar : PubMed/NCBI
36	Wang X, Lu X, Geng Z, Yang G and Shi Y: LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via wnt/β-catenin signaling. J Cell Biochem. 118:4745–4752. 2017. View Article : Google Scholar : PubMed/NCBI
37	Lai Z, Lin P, Weng X, Su J, Chen Y, He Y, Wu G, Wang J, Yu Y and Zhang L: MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease. Biomed Pharmacother. 97:162–167. 2018. View Article : Google Scholar
38	Ku T, Li B, Gao R, Zhang Y, Yan W, Ji X, Li G and Sang N: NF-κB-regulated microRNA-574-5p underlies synaptic and cognitive impairment in response to atmospheric PM2.5 aspiration. Part Fibre Toxicol. 14:342017. View Article : Google Scholar
39	Khaled WT, Choon Lee S, Stingl J, Chen X, Raza Ali H, Rueda OM, Hadi F, Wang J, Yu Y, Chin SF, et al: BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat Commun. 6:59872015. View Article : Google Scholar : PubMed/NCBI
40	Errico A: Genetics: BCL11A-targeting triple-negative breast cancer? Nat Rev Clin Oncol. 12:1272015. View Article : Google Scholar : PubMed/NCBI
41	Liu DW, Zhang JH, Liu FX, Wang XT, Pan SK, Jiang DK, Zhao ZH and Liu ZS: Silencing of long noncoding RNA PVT1 inhibits podocyte damage and apoptosis in diabetic nephropathy by upregulating FOXA1. Exp Mol Med. 51:882019. View Article : Google Scholar :